Compare MD & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MD | STOK |
|---|---|---|
| Founded | 1979 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.0B |
| IPO Year | 1996 | 2019 |
| Metric | MD | STOK |
|---|---|---|
| Price | $20.08 | $34.65 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | $20.00 | ★ $36.10 |
| AVG Volume (30 Days) | ★ 843.2K | 587.7K |
| Earning Date | 05-20-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 263.03 | 30.67 |
| EPS | ★ 1.94 | 0.85 |
| Revenue | ★ $1,913,849,000.00 | $36,555,000.00 |
| Revenue This Year | $3.72 | $428.68 |
| Revenue Next Year | $2.62 | N/A |
| P/E Ratio | ★ $10.27 | $40.59 |
| Revenue Growth | N/A | ★ 316.34 |
| 52 Week Low | $11.84 | $5.35 |
| 52 Week High | $24.99 | $39.81 |
| Indicator | MD | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 43.52 | 54.65 |
| Support Level | $16.41 | $30.50 |
| Resistance Level | $22.47 | $34.95 |
| Average True Range (ATR) | 0.85 | 2.24 |
| MACD | -0.03 | 0.09 |
| Stochastic Oscillator | 55.90 | 43.02 |
Pediatrix Medical Group Inc provides physician services to hospitals, intensive care units, and other medical units. The services provided by the company include maternal care for expectant mothers, intensive care for premature babies, cardiology care for infants suffering from heart defects, and anesthesia care during surgeries, among others. The company operates only under one segment which provides physician services including newborn, maternal-fetal, and other pediatric subspecialty care. It generates majority of the revenue through neonatology and other pediatric subspecialties.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.